Depósito Digital de Documentos de la UAB Encontrados 2 registros  La búsqueda tardó 0.01 segundos. 
1.
9 p, 801.8 KB PD-1 Blockade in Anaplastic Thyroid Carcinoma / Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; Wirth, Lori J. (Harvard Medical School) ; Ernst, Thomas (Universitätsklinikum Jena) ; Ponce Aix, Santiago (Hospital Universitario 12 de Octubre (Madrid)) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Ramlau, Rodryg (Poznań University of Medical Sciences) ; Butler, Marcus O. (Princess Margaret Cancer Centre) ; Delord, Jean-Pierre (IUCT Oncopole) ; Gelderblom, Hans J (Leiden University Medical Center) ; Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G. Pascale) ; Fasolo, Angelica (San Raffaele Hospital) ; Führer, Dagmar (University Hospital Essen (Alemanya)) ; Hütter-Krönke, Marie Luise (University Hospital of Ulm (Alemanya)) ; Forde, Patrick M. (Sidney Kimmel Comprehensive Cancer Center) ; Wrona, Anna (Uniwersyteckie Centrum Kliniczne) ; Santoro, Armando (IRCCS Humanitas University) ; Sadow, Peter M. (Harvard Medical School) ; Szpakowski, Sebastian (Novartis Institutes for BioMedical Research) ; Wu, Hongqian (Novartis Pharmaceuticals) ; Bostel, Geraldine (Novartis Institutes for BioMedical Research) ; Faris, Jason (Novartis Institutes for BioMedical Research) ; Cameron, Scott (Novartis Institutes for BioMedical Research) ; Varga, Andreea (Gustave Roussy Cancer Campus) ; Taylor, Matthew (Oregon Health & Science University) ; Universitat Autònoma de Barcelona
Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF -wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor. [...]
2020 - 10.1200/JCO.19.02727
Journal of Clinical Oncology, Vol. 38 Núm. 23 (may 2020) , p. 2620-2627  
2.
10 p, 426.6 KB A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies / Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Delord, Jean-Pierre (Institut Claudius Regaud (France)) ; Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ; Berge, Y. (Institut Claudius Regaud (France)) ; Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ; Cottura, E. (Institut Claudius Regaud (France)) ; Bedard, Philippe L (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Akimov, Mikhail (Novartis Pharma AG (Switzerland)) ; Lu, H. (Novartis Pharmaceuticals Corp (USA)) ; Pain, S. (Novartis Pharmaceuticals Corp (USA)) ; Kaag, A. (Novartis Pharma AG (Switzerland)) ; Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.